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Effects of hemodialysis dose and membrane flux on health-
related quality of life in the HEMO Study.
Background. It has been widely supposed that high dose and
high flux hemodialysis would affect the quality as well as the
length of life of patients treated by maintenance hemodialysis.
The HEMO Study examined changes in health-related qual-
ity of life as a secondary study outcome. Specific hypotheses
were that study interventions would affect physical function-
ing, vitality, Short Form-36 Health Survey (SF-36) physical and
mental component summary scores, symptoms and problems
associated with kidney disease, and sleep quality.
Methods. At baseline and annually, subjects responded to
both the Index of Well-Being and the Kidney Disease Qual-
ity of Life-Long Form questionnaires. The interventions were
assessed on the basis of their average effects over 3 years.
Results. At baseline, the SF-36 physical component summary
score was lower than in healthy populations, but the mental
component score was nearly normal. Over 3-year follow-up,
physical health continued to decline; mental health and kid-
ney disease-targeted scores remained relatively stable. The high
dose hemodialysis intervention was associated with significantly
less pain (4.49 points, P < 0.001) and higher physical component
scores (1.23 points P = 0.007), but these effects were small com-
pared to the natural variability in scores. High flux membranes
were not associated with statistically significant differences in
health-related quality of life.
Conclusion. The HEMO Study results demonstrate the
marked burden of chronic kidney failure and hemodialysis
treatment on daily life. In this trial among patients undergo-
ing maintenance three times a week hemodialysis, the SF-36
physical component summary score and pain scale showed sig-
nificant but very small clinical effects favoring the higher dialysis
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dose. No clinically meaningful benefits or either the dose or flux
interventions were observed for other indices of health-related
quality of life.
While a number of therapies and technologies have
been reported to increase health-related quality of life in
chronic kidney failure, patients report that they remain
substantially burdened by limited physical functioning
and by dialysis-related symptoms [1–6]. Indeed, health-
related quality of life may be the most critical outcome for
those undergoing hemodialysis [7]. Furthermore, health-
related quality of life has been associated with nutri-
tional outcomes, hospitalizations, and survival in patients
with end-stage renal disease (ESRD) [8–11]. The HEMO
Study, a multicenter prospective randomized study de-
signed to examine the effects of hemodialysis dose and
membrane flux on morbidity and mortality, also sought to
assess the impact of these on health-related quality of life.
The HEMO Study adopted a concept of health-related
quality of life that included physical functioning, mental
well being, social functioning, dialysis related symptoms,
and patient satisfaction.
Relationships between hemodialysis dose and patient
outcomes were first elucidated by the National Coopera-
tive Dialysis Study [12]. Subsequent observational studies
suggested that increased dialysis dose was associated with
improved survival [13]. However, no randomized trials of
dialysis dose have examined its effects on health-related
quality of life.
Neither has the impact of high flux hemodialysis mem-
branes on health-related quality of life been evaluated,
although limited data suggest that high flux can reduce
dialysis symptoms and preserve physical functioning [14–
18]. The high flux membrane removes larger molecular
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weight solutes, including b 2 microglobulin, which can be
associated a lower incidence of b 2 microglobulin-related
amyloidosis and therefore diminish joint pain [15–19].
The HEMO Study examined the effects on hemodial-
ysis patient survival of dose (eKt/V 1.45 vs. 1.05) and
hemodialyzer flux (high vs. low). We hypothesized that
the interventions would significantly benefit physical
functioning, vitality, Short Form-36 Health Survey (SF-
36) physical and mental component summary scores, kid-
ney disease symptoms, and sleep quality.
METHODS
Study design
The HEMO Study was a 15-center randomized clinical
trial of the effects of hemodialysis dose and membrane
flux on mortality and morbidity in patients undergoing
chronic dialysis [20]. Patients in this study were random-
ized to either standard or high dose (eKt/V 1.05 vs. 1.45,
respectively) and to either high or low flux membranes
(b 2 microglobulin clearance <10 mL/min or >20 mL/min,
respectively).
Patient eligibility criteria have been described previ-
ously [21]. The primary end point was all-cause mortality
[22]. The Institutional Review Boards at the 15 institu-
tions approved the study protocol and written informed
consent was obtained from all study participants. Enroll-
ment in the HEMO Study began in March 1995 and ended
in October 2000.
At randomization and annually during 3 years of
follow-up, HEMO Study patients responded to a survey
as previously described [23, 24], including the Index of
Well-Being (IWB) and the Kidney Disease Quality of
Life-Long Form (KDQOL-LF) questionnaire [25, 26].
The HEMO health-related quality of life battery of in-
struments and scoring, as well as supplemental items are
provided at http://www.bio.ri.ccf.org/Research/HEMO/
index.html.
Health-related quality of life instruments
The IWB consists of ten bipolar items on which the
patient indicates how he or she feels about life and one
bipolar item asking how satisfied a patient currently feels
about his or her life [27]. The range for the IWB is 2.1
(low well-being) to 14.7 (high well-being). The IWB has
been shown to be reliable and valid both in chronic kidney
failure and in other populations [25].
The KDQOL-LF assesses generic and kidney disease–
targeted health-related quality of life domains. The SF-
36 consists of 36 items, 35 of which are aggregated into
eight multi-item scales that measure physical functioning,
role physical, bodily pain, general health, vitality, social
functioning, role emotional, and mental health. The range
of scores for the SF-36 subscales was 0 to 100, with a
higher score reflecting better health and well-being (e.g.,
higher bodily pain score means less self-reported pain).
The eight scales also are scored to produce two summary
measures of physical (physical component summary) and
mental health (mental component summary) [28]. In the
general population, the mean score for each summary
scale is 50 points with a standard deviation of 10 points
[28].
The KDQOL family of survey instruments has been
widely used in dialysis studies and has shown adequate
reliability, validity, and responsiveness among diverse pa-
tient populations [26, 29–31]. The internal consistency re-
liability and distribution of KDQOL-LF scores have been
previously described in the HEMO Study population [23,
24]. Because it had less than adequate internal consis-
tency reliability, we excluded the KDQOL-LF social in-
teraction scale from this analysis. The range of scores for
the dialysis-targeted scales was 0 to 100, with a higher
score reflecting better health.
The HEMO Study included supplemental treatment-
specific and condition-specific items regarding symptoms
before, during, and after hemodialysis. These items had
been created by HEMO Study investigators and pilot
tested in a sample of patients at one center. In order
to further assess the effect of dialysis dose on pain, we
examined the effect of dialysis dose and membrane flux
on ten additional items related to pain: one item from
the KDQOL-LF assessing overall pain on average in the
previous 4 weeks; headache, bone and joint, or back pain
before dialysis in the previous 2 weeks; muscle cramps af-
ter dialysis; and headache, chest pain, muscle cramps, pain
in dialysis access, bone and joint pain, or back pain during
hemodialysis. These items were not scaled but have face
validity and the item response rate of 97.5% for these
items indicates that participants were able to understand
the items.
Interventions and data collection
General data collection procedures have been de-
scribed previously [20]. Health-related quality of
life questionnaires were either self-administered or
interviewer-administered. Research coordinators admin-
istered an interview version of the survey to patients who
were unable to self-administer the form due to physical
impairment, or who stated a strong preference for the
interview format. Interviewers were directed to read the
survey verbatim, and not to rephrase items.
Statistical methods
Demographic and laboratory factors are described as
means for continuous variables and frequency for di-
chotomous variables. Differences between groups were
assessed using two sample t statistics for interval or ratio-
level variables (e.g., age). Chi-squared tests were used for
categorical variables (e.g., race).
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Analysis of changes in health-related quality of life is
often complicated by patient attrition [32–35]. High rates
of death and kidney transplantation make this issue par-
ticularly salient in dialysis studies. The overall mortal-
ity rate in the HEMO Study was 16.6% per year, and
the combined attrition rate for mortality, transplantation,
dialysis modality switches, and transfers to nonstudy dial-
ysis units exceeded 23% per year. The subgroups of pa-
tients providing data at successive follow-up assessments
are thus not strictly comparable. Those patients surviving
to later follow-up assessments were, on average, in better
health when they entered the study than were those who
subsequently died.
To control for this potential bias, mean changes in each
health-related quality of life scale were estimated from
baseline to each follow-up time point using a statistical
model for the mean change in all randomized patients,
including those who died or otherwise dropped out [36,
37]. Because the mean changes of this statistical model
incorporate patients who die early in the study, they tend
to be more negative (reflecting greater declines in health-
related quality of life over time) than the corresponding
mean changes in the subgroups of patients who survive
to the respective time points during follow-up.
The mean changes on the health-related quality of life
scales were analyzed using a mixture model for infor-
mative censoring [36, 38] in which the rate of censored
(or missing) data may be related to the patients’ missing
health-related quality of life scores. This general ap-
proach has recently been advocated for analysis of longi-
tudinal changes in quality of life variables in the presence
of dropout [35]. The Appendix gives a complete descrip-
tion of the informative censoring model used and this
methodology has been previously described for nutri-
tional outcomes in the HEMO Study [39]. We provide
a general overview here. The effect of dropout on the
quality of life scores was modeled using three “censor-
ing variables” which describe the length of follow-up,
indicate whether the patient died, and capture the inter-
action between these two factors. The analysis involved
two steps. In the first step, a multivariate model account-
ing for multiple measurements in the same patients was
used to estimate the mean changes to each annual follow-
up assessment within each treatment group on a qual-
ity of life scale conditionally given the values of the
three censoring variables, while adjusting for the seven
prespecified baseline factors [age, gender, race, diabetic
status, years of prior dialysis, baseline albumin, and base-
line Index of Coexistent Disease (ICED) comorbidity
score] and the baseline level on the quality of life scale.
In the second step, the results obtained in the first step
were averaged over the distributions of the censoring
variables separately within each treatment group to es-
timate the mean changes in the quality of life scale at
each follow-up time adjusted to the average values of
the censoring variables within the respective treatment
groups.
The “main effects” of the dose and flux interventions
were obtained by averaging over the patients assigned
to the two levels of the other intervention. In order to
use a single assessment that extended over multiple time
points, the average of the effects at years 1, 2, and 3 was
selected as the main criterion for statistical assessment of
the effects of the interventions. The interactions between
the dose and flux interventions were also tested for the
average effect over 3 years.
The high attrition rate makes the method used to ac-
count for deaths and dropouts particularly important.
Thus, as is widely recommended for informative censor-
ing models [32–35], sensitivity analyses were conducted to
determine whether the results of the dose and flux group
comparisons were consistent under different models for
the missing data. Specifically, the censoring variables in
the mixture model were expanded to distinguish among
termination of follow-up due to kidney transplantation,
due to death, and due to administrative censoring at the
end of the study. We also considered several different
models describing the relationship between the censor-
ing variables and the pattern of change in quality of life
over time, and for extrapolating the mean quality of life
scores beyond the time of dropout. An additional sen-
sitivity analysis was conducted by eliminating patients
who switched between the oral and written versions of
the quality of life questionnaire, in order to ensure that
treatment group comparisons were not biased by use of
different forms of the questionnaire at different times.
We regard the hypotheses of effects on different health-
related quality of life dimensions as nonexchangeable and
distinct. Therefore, to avoid the loss of statistical power
associated with a multiple-comparisons adjustment,
P values for the effects of the interventions on the in-
dividual health-related quality of life scales were calcu-
lated on a comparison-wise basis for each scale, without
adjustment for multiple comparisons. However because
so many health-related quality of life indices were an-
alyzed, we also examined the implications of treatment
effects in the context of multiple analyses. We did this by
considering two levels of Bonferroni adjustment. While
they were still blinded to the outcome results, the inves-
tigators designated the SF-36 physical and mental com-
ponent summary scales, the SF-36 physical functioning
and vitality scales, and the KDQOL-LF sleep and symp-
toms/problems scales as having primary status. The inves-
tigators considered these scales the most likely to reflect
hypothesized intervention effects on health-related qual-
ity of life. For these six scales, the Bonferroni-adjusted
significance level for each intervention is 0.0083. For the
remaining 11 scales we used the more stringent
Bonferroni-adjusted critical value of 0.0029 associated
with a total of 17 analyses. Treatment effects which fail
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Table 1. HEMO Study baseline patient characteristicsa
Characteristic All HEMO Standard Kt/V High Kt/V Low flux High flux
Ageb years 57.59 (14.0) 57.75 (14.0) 57.62 (14.1) 57.48 (14.2) 57.7 (13.9)
Female % 56.26 56.26 56.26 55.62 56.91
Race %
African American 63.65 65.16 62.13 63.66 63.65
White 33.98 32.53 35.44 33.59 34.36
Other 2.37 2.31 2.44 2.75 1.99
Diabetic % 44.73 44.84 44.63 44.71 44.75
Hypertensive % 96.1 96.0 96.1 95.8 96.4
Dialysis durationb years 3.75 (4.4) 3.66 (4.27) 3.66 (4.27) 3.71 (4.26) 3.8 (4.47)
Interview % 39.6 40.3 38.9 39.1 40.1
Employment %
Working 11.69 12.31 11.07 12.11 11.27
Retired/unknown 38.11 38.24 37.98 38.22 38.01
Not working 50.19 49.45 50.94 49.67 50.72
At least high school education % 62.27 63.48 61.04 62.07 62.46
Comorbidity score %
ICED 0–1 35.47 34.84 36.10 36.67 34.25
ICED 2 31.00 30.77 31.23 31.17 30.83
ICED 3 33.54 34.40 32.67 32.16 34.92
High flux % 59.93 59.3 60.58 58.81 61.06
eKt/Vb 1.42 (0.24) 1.43 (0.24) 1.42 (0.24) 1.42 (0.24) 1.43 (0.24)
Body mass indexb kg/m2 25.5 (5.3) 25.56 (5.23) 25.44 (5.35) 25.38 (5.13) 25.63 (5.45)
Albuminb g/dL 3.62 (0.4) 3.61 (0.39) 3.63 (0.39) 3.61 (0.39) 3.63 (0.39)
Hematocrit % 33.6 (4.5) 33.63 (4.45) 33.53 (4.57) 33.63 (4.48) 33.53 (4.54)
Phosphateb mg/dL 5.78 (1.9) 5.75 (1.89) 5.81 (1/87) 5.77 (1.83) 5.79 (1.93)
Treatment timeb minutes 214.1 (25.5) 214.2 (26.2) 213.9 (24.8) 213.6 (25.9) 214.5 (25.1)
Follow-up treatment timeb,c minutes 205.2 (29.4) 190.8 (25.8) 219.3 (25.8) 207.4 (30.2) 203.1 (28.5)
ICED is Index of Coexistent Disease.
aNo significant differences in baseline characteristics by treatment arms (all P > 0.05); bmean (standard deviation); cP < 0.0001.
to meet the appropriate Bonferroni criteria but which
have unadjusted P < 0.05 are interpreted as hypothesis
generating.
RESULTS
HEMO Study patient characteristics
A total of 2677 hemodialysis patients were screened;
1846 were randomized, and 1813 (98%) completed the
health-related quality of life questionnaire at baseline.
The 33 patients who did not respond to the survey did
not speak either English or Spanish. Table 1 shows rel-
evant sociodemographic and clinical characteristics of
the 1813 respondents. Their average age was 57.6 years,
56% were female, and two thirds were African Ameri-
can. A majority of the patients had diabetes or hyperten-
sion as the cause of chronic kidney failure, and approx-
imately one third had the highest possible comorbidity
index score. The average duration of dialysis was 3.75
years. Sixty percent were on high flux dialysis membranes
at baseline; the average equilibrated Kt/V before ran-
domization was 1.42. The average albumin was 3.6 g/dL
and mean hematocrit was 33.6%. The number classified
as working was 11.69%. Nearly 40% of respondents re-
quired an interviewer-administered questionnaire. There
were no substantial differences in baseline characteristics
between randomized groups. Table 2 shows the overall
mean changes in the respective quality of life scales with-
Table 2. HEMO Study patients: Longitudinal changes in average
health-related quality of life scoresa
Mean Mean Mean
Baseline change change change
score year 1 year 2 year 3
Domains mean (SD) baseline baseline baseline
Index of Well-Being 10.0 (2.9) −0.2 −0.2 −0.4
Physical functioning 48.1 (26.9) −2.5 −3.8 −5.6
Role, physical 44.0 (40.5) −1.3 −2.4 −2.1
Bodily pain 62.8 (27.9) −2.0 −2.9 −4.7
General health 46.3 (21.2) −0.8 −1.6 −3.6
Vitality 50.0 (21.8) −2.0 −3.8 −4.0
Social functioning 70.6 (27.0) −2.2 −2.5 −3.7
Role, emotional 63.8 (41.9) 0.4 −0.6 −0.7
Mental health 71.6 (19.3) −1.7 −1.6 −1.6
Physical component 35.7 (10.1) −0.9 −1.3 −2.1
summary score
Mental component 49.9 (10.9) −0.4 −0.7 −0.4
summary score
Symptom/problem 75.3 (14.1) −1.0 −1.2 −1.8
Effects 66.1 (20.9) 0.1 −0.0 −0.1
Burden 50.5 (29.3) 0.9 0.9 1.0
Cognitive function 75.4 (20.6) −1.3 −1.0 −0.3
Sleep 58.7 (22.7) −1.4 −1.0 −1.8
Social support 66.9 (23.0) −2.8 −2.2 −2.3
Staff encouragement 68.2 (17.1) −1.8 −1.8 −2.3
Patient satisfaction 69.2 (20.0) −2.7 −4.5 −4.7
aShown are mean scores at baseline and mean changes from baseline to years
1, 2, and 3 of follow-up using all available data for each analysis, without statistical
adjustment for baseline covariates or attrition over time.
out adjustment for baseline covariates or for dropout. The
number of respondents decreased from 1813 at baseline
by 27% at year 1, 53% at year 2, and 67% at year 3.
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Fig. 1. The mean change in physical function is shown for dose (stan-
dard vs. high Kt/V) (A) and flux (low vs. high flux) (B) interventions. In
each panel, mean changes adjusted for baseline covariates (age, albu-
min, iced, duration of dialysis, race, gender, diabetic status, and baseline
quality of life) under the informative censoring model are denoted by
circles, and the unadjusted mean changes by diamonds. The error bars
represent 95% CI.
Effects of dose and flux interventions
There were no significant interactions between the
dose and flux interventions (P > 0.10 for the analysis of
the average effect at years 1 to 3 for each quality of life
scale). Hence, we report the overall main effect of each
intervention, averaging over both levels of the other in-
tervention. Figures 1 to 7 show the mean changes in scale
scores for the seven domains for which effects were hy-
pothesized, as well as for bodily pain, for which an unan-
ticipated effect was observed. The figures show both the
unadjusted mean change for each randomized group and
the mean change adjusted for baseline covariates and ac-
counting for attrition based on the informative censoring
model. The adjusted results formed the basis for the sta-
tistical interpretation. It can be seen that the mean differ-
ences between the treatment groups were similar for the
unadjusted and adjusted analyses for each index. How-
ever, as expected, the average overall declines within each
treatment group are generally smaller for the unadjusted
analysis, reflecting the cumulative attrition of sicker
patients.
The two panels of Figure 1 show change in physical
functioning scores by dose and flux groups, respectively.
Physical functioning scores of the dose groups appear to
diverge after the first year (P = 0.061). In Figure 1B, the
two flux groups remain virtually identical. Figure 2 shows
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Fig. 2. The mean change in bodily pain is shown for dose (standard
vs. high Kt/V) (A) and flux (low vs. high flux) (B) interventions. In
each panel the adjusted mean changes are denoted by circles and the
unadjusted mean changes by diamonds. The error bars represent 95%
CI.
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Fig. 3. The change in vitality is shown for dose (standard vs. high Kt/V)
(A) and flux (low vs. high flux) (B) interventions. In each panel the
adjusted mean changes are denoted by circles and the unadjusted mean
changes by diamonds. The error bars represent 95% CI.
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Fig. 4. The change in physical component summary score being is
shown for dose (standard vs. high Kt/V) (A) and flux (low vs. high
flux) (B) interventions. In each panel the adjusted mean changes are
denoted by circles and the unadjusted mean changes by diamonds. The
error bars represent 95% CI.
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Fig. 5. The change in mental component summary score is shown for
dose (standard vs. high Kt/V) (A) and flux (low vs. high flux) (B) in-
terventions. In each panel the adjusted mean changes are denoted by
circles and the unadjusted mean changes by diamonds. The error bars
represent 95% CI.
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Fig. 6. The change in symptoms of kidney disease is shown for dose
(standard vs. high Kt/V) (A) and flux (low vs. high flux) (B) interven-
tions. In each panel the adjusted mean changes are denoted by circles
and the unadjusted mean changes by diamonds. The error bars repre-
sent 95% CI.
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Fig. 7. The change in sleep is shown for dose (standard vs. high Kt/V)
(A) and flux (low vs. high flux) (B) interventions. In each panel the
adjusted mean changes are denoted by circles and the unadjusted mean
changes by diamonds. The error bars represent 95% CI.
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Table 3. Effect of dose intervention on health-related quality of life domainsa
Year 1 BS Year 2 BS Year 3 BS
Domains effect (SE) effect (SE) effect (SE) Average effect P value
Index of Well-Being 0.07 (0.15) 0.31 (0.18) 0.04 (0.23) 0.14 (0.13) P = 0.29
Physical functioning 0.12 (1.13) 4.33 (1.45) 1.91 (1.87) 2.12 (1.13) P = 0.061
Role, physical −1.89 (2.09) 4.72 (2.65) 3.68 (3.18) 2.17 (1.88) P = 0.248
Bodily pain 3.13 (1.35) 6.21 (1.71) 4.14 (2.05) 4.49 (1.25) P = 0.0003b
General health −0.11 (0.96) 2.51 (1.21) 0.22 (1.41) 0.87 (0.90) P = 0.33
Vitality 0.68 (0.99) 3.07 (1.20) 0.84 (1.41) 1.53 (0.88) P = 0.082
Social functioning −0.15 (1.31) 3.15 (1.69) −1.40 (2.08) 0.53 (1.19) P = 0.65
Role, emotional −3.41 (2.17) 2.67 (2.74) 2.28 (3.39) 0.51 (1.91) P = 0.79
Mental health −0.54 (0.90) 0.80 (1.14) −1.29 (1.42) −0.34 (0.84) P = 0.68
Physical component summary score 0.19 (0.47) 2.03 (0.60) 1.46 (0.73) 1.23 (0.46) P = 0.007b
Mental component summary score −0.48 (0.55) 0.71 (0.70) −0.71 (0.86) −0.16 (0.49) P = 0.75
Symptom/problem 0.71 (0.59) 1.56 (0.71) 0.61 (0.88) 0.96 (0.54) P = 0.077
Effects of kidney disease −0.29 (0.87) 1.43 (1.10) 0.32 (1.31) 0.49 (0.82) P = 0.55
Burden of kidney disease −0.10 (1.26) 1.65 (1.56) −2.80 (1.87) −0.42 (1.17) P = 0.72
Cognitive function 1.82 (0.90) 0.28 (1.13) 0.04 (1.36) 0.71 (0.83) P = 0.39
Sleep 0.81 (1.00) 1.52 (1.35) 3.12 (1.52) 1.81 (0.95) P = 0.057
Social support −1.18 (1.00) 0.74 (1.25) −0.55 (1.58) −0.33 (0.92) P = 0.72
Staff encouragement 0.11 (0.83) 2.89 (1.12) 1.21 (1.27) 1.40 (0.76) P = 0.065
Patient satisfaction −0.70 (0.98) −0.95 (1.15) −4.45 (1.48) −2.04 (0.87) P = 0.020
aShown are estimated mean differences between high and standard dose groups adjusted for baseline covariates (age, albumin, iced, duration of dialysis, race, gender,
diabetic status, and baseline quality of life) under the informative censoring model. Domains in bold were hypothesized to demonstrate effects by HEMO Committee
bStatistically significant after adjustment for multiple comparisons.
Table 4. Effect of flux intervention on health-related quality of life domainsa
Year 1 BS Year 2 BS Year 3 BS
Domains effect (SE) effect (SE) effect (SE) Average effect P value
Index of Well-Being −0.20 (0.15) 0.16 (0.18) −0.03 (0.23) −0.02 (0.13) 0 = 0.87
Physical functioning −0.35 (1.14) 0.51 (1.45) 0.71 (1.88) 0.29 (1.13) P = 0.80
Role, physical 0.91 (2.09) −2.12 (2.65) 0.89 (3.18) −0.11 (1.88) P = 0.95
Bodily pain 1.55 (1.34) −0.15 (1.71) 1.43 (2.06) 0.94 (1.25) P = 0.45
General health 1.12 (0.96) −0.43 (1.21) 0.53 (1.41) 0.41 (0.90) P = 0.65
Vitality −0.19 (1.00) 0.02 (1.20) 0.85 (1.42) 0.23 (0.88) P = 0.79
Social functioning 0.68 (1.31) 0.47 (1.68) −1.50 (2.09) −0.12 (1.19) P = 0.92
Role, emotional 1.11 (2.17) 1.48 (2.74) 0.76 (3.40) 1.12 (1.92) P = 0.56
Mental health −0.95 (0.90) 1.54 (1.13) −1.62 (1.42) −0.34 (0.84) P = 0.68
Physical component summary score 0.26 (0.47) −1.00 (0.61) 0.49 (0.73) −0.08 (0.46) P = 0.86
Mental component summary score 0.003 (0.55) 0.83 (0.70) −0.62 (0.86) 0.07 (0.50) P = 0.88
Symptom/problem −0.22 (0.59) 0.83 (0.71) 2.07 (0.88) 0.89 (0.54) P = 0.10
Effects of kidney disease −0.61 (0.87) 0.12 (1.10) −0.63 (1.31) −0.38 (0.82) P = 0.65
Burden of kidney disease −1.94 (1.26) −0.16 (1.56) 1.47 (1.88) −0.21 (1.18) P = 0.86
Cognitive function 0.87 (0.90) 1.04 (1.13) 1.12 (1.36) 1.01 (0.83) P = 0.23
Sleep 0.56 (1.00) 2.95 (1.35) 3.26 (1.53) 2.25 (0.95) P = 0.018
Social support −1.01 (1.00) 2.71 (1.25) 1.22 (1.59) 0.97 (0.92) P = 0.29
Staff encouragement −0.81 (0.83) −0.29 (1.11) 0.46 (1.28) −0.21 (0.76) P = 0.78
Patient satisfaction 0.85 (0.98) 1.99 (1.15) 3.51 (1.48) 2.12 (0.88) P = 0.016
aShown are estimated mean differences between high and low membrane flux groups adjusted for baseline covariates (age, albumin, iced, duration of dialysis, race,
gender, diabetic status, and baseline quality of life) under the informative censoring model. Domains in bold were hypothesized to demonstrate effects by HEMO
Committee.
that the standard dose group had a larger decrease in
bodily pain score during follow up than the high dose
group (P = 0.0003). Figure 3 shows that physical compo-
nent summary scores declined more in the standard dose
group than in the high dose group (P = 0.007). Figures 4
to 7 show changes during follow up in vitality, sleep, symp-
toms of kidney disease, and mental component summary
scores, respectively. These scores did not differ signif-
icantly between either the dose or flux groups during
follow-up.
Tables 3 and 4 demonstrate the effects of the dose
and flux interventions for all domains after adjusting
for baseline covariates and for attrition. Table 3 shows
the effects of high dose compared to the standard dose
under the unconditional informative censoring model ad-
justed for baseline differences in age, albumin, comor-
bidity score, duration of dialysis, race, gender, diabetic
status, and health-related quality of life score. The scales
for which the investigators hypothesized effects are dis-
played in bold type. On most health-related quality of
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Fig. 8. The effects of model assumptions on
average change in physical component score.
The symbol × indicates unadjusted mean
change using all available data. Model 1 in-
corporates an accelerated decline in the year
prior to death, and assumes that the mean rate
of change subsequently reverts to the mean
rate of change for surviving patients. Model
2 assumes that the accelerated decline in the
year before death persists for the remainder
of follow-up. Model 3 excludes the accelerated
decline both during the year before death and
subsequently.
life scales, there was no significant difference between in
scores by dose groups. However, the mean decline bodily
pain was slower in the high dose group than the standard
dose group, by 3.13 points at year 1, 6.21 points at year 2,
and 4.14 points at year 3. The average effect of the dose
effects on bodily pain over years 1, 2, and 3 was 4.49 ±
1.25 units (P = 0.0003), which represents an effect size of
0.16. In addition, the physical component summary de-
clined more slowly in the high dose than the standard
dose groups, with mean differences of 0.19 at year 1, 2.03
at year 2, and 1.46 points at year 3. The average of the
dose effects on physical component summary scores over
years 1, 2, and 3 was 1.23 ± 0.46 (P = 0.007), which rep-
resents an effect size of 0.12. The sleep quality index also
tended to decline more slowly in the high dose compared
to the standard dose group, with an average difference
between dose groups over years 1, 2, and 3 of 1.81 ± 0.95
(P = 0.057). The patients in the high dose group reported
less satisfaction with care than the standard dose group
during years 1, 2, and 3, with a mean difference between
dose groups of −2.04 ± 0.87 (P = 0.020).
The effect of the dose intervention on the physical com-
ponent summary score remains statistically significant un-
der the multiple comparison criterion of P < 0.0083 for
the prespecified scales. Among the remaining 11 indices,
the effect of the dose intervention on bodily pain, with P <
0.001, remains significant after Bonferroni adjustment for
the 17 independent health-related quality of life indices
considered in this report, and thus does not appear com-
patible with chance. However, because the effects of dose
interventions on the sleep and patient satisfaction scores
do not meet the stricter significance criterion, we inter-
pret these as hypothesis generating
Table 4 compares adjusted high flux effects to low flux.
Only in sleep and patient satisfaction were substantial
differences observed between flux groups. For sleep, the
mean of the sleep quality scale was higher in the high flux
group by 0.56 points at year 1, 2.95 points at year 2, and
3.26 points at year 3. The mean difference in the sleep
quality between the flux groups over years 1, 2, and 3 was
2.25 ± 0.95 (P = 0.018). High flux patients also reported
greater patient satisfaction than low flux patients, with
mean differences between the flux groups of 0.85 points
at year 1, 1.99 points at year 2, and 3.51 points at year 3.
The mean effect over years 1, 2, and 3 was 2.12 ± 0.88 (P =
0.016). However, because the effects of flux interventions
on the sleep and patient satisfaction scores do not meet
the stricter significance criterion, we interpret these as
hypothesis generating.
In order to examine the robustness of the bodily pain
findings, we performed an analysis to determine the effect
of dialysis dose and flux on ten additional items related
to pain. There were no significant effects of dialysis dose
(all P > 0.05) on an additional item assessing overall pain
on average in the last 4 weeks, and nine items assessing
pain for 2 weeks before, during, and after hemodialysis
treatments.
Sensitivity analyses
We repeated the analyses of Figures 1 to 7 and Tables 3
and 4 using alternative variations of the informative cen-
soring model with additional terms to distinguish be-
tween patients censored because of kidney transplanta-
tion and surviving patients who completed the study or
who dropped for other reasons. The results were essen-
tially unchanged.
Informative censoring models entail assumptions
about changes that would have been observed absent pa-
tient loss to attrition [34, 40, 41]. To address this issue, the
mean changes in health-related quality of life scale scores
were evaluated under three different models. Using the
physical component summary scores of patients random-
ized to standard dose as an example, Figure 8 illustrates
these three informative censoring models, as well as the
analysis of raw mean changes to each follow-up year.
These informative censoring models differ in the way they
extrapolate the scale scores observed in the final year
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before to death to time points after death. Model 1 incor-
porates an accelerated decline in quality of life during the
year before death, but then assumes that the mean rate of
change after death reverts to the mean rate of change for
patients who did not die until at least 1 year after the
current time point. This is the model used for the “main
analysis” presented in Figures 1 to 7 and Tables 3 and 4.
Model 2 assumes that the accelerated decline observed in
the year before death persists throughout the remainder
of follow-up. Model 3 excludes the accelerated decline
both during the year before death and during subsequent
follow-up. These three informative censoring models, as
well as the analysis of mean changes to each follow-up
year without adjustment for censoring, all yielded similar
results with respect to the comparisons of the dose and
flux groups. This finding is consistent with the observation
that the rates of the major sources of attrition (mortality,
transplant, and transfer to nonparticipating dialysis facil-
ities) did not differ significantly between the treatment
groups [20]. The similarity of results from the three mod-
els suggests that the main results (from model 1) are not
artifacts of a particular method of accounting for dropout.
On the other hand, for several of the scales, the overall
estimate of the rate of mean decline over time did differ
substantially among the different models. The estimated
mean declines were fastest under model 2, slowest under
model 3, and intermediate under model 1. Thus, while the
differences between the treatment groups are similar for
each model, Figure 8 shows uncertainty in the assessment
of the overall mean rate of decline within the treatment
groups. This uncertainty reflects an inherent indetermi-
nacy in the description of change in a cohort with a high
rate of attrition.
We also sought evidence that the comparisons of the
randomized treatment groups might be confounded by
changes in the modality of administration of the quality
of life questionnaire (self-administered vs. interviewer-
administered). The rate at which patients changed modal-
ity of administration between baseline and follow-up was
similar between the dose and flux groups. The compar-
isons of the scale scores between randomized groups at
the individual follow-up assessments also generally gave
similar results, whether the analysis was restricted to pa-
tients using the same mode of administration for both
the baseline and follow-up assessments, or whether the
analyses included all available patients.
DISCUSSION
While this multicenter randomized trial of hemodial-
ysis dose and membrane flux shows that higher dose
hemodialysis treatment was associated with a signifi-
cantly slower decline in physical health and with slower
worsening in bodily pain than standard dose treatment,
the effects were small. Indeed, the bodily pain finding did
not appear to be robust, since individual items assessing
overall pain, as well as pain before and during dialysis
treatments, were not significantly impacted by dialysis
dose. Both high dose and high flux were associated with
a trend to higher mean sleep scores during follow-up.
However, this effect did not reach statistical significance
after adjustment for multiple comparisons. This lack of
a clinically important effect was found despite a clear
separation in the fractional urea clearance and in the b 2
microglobulin clearance between the treatment groups.
While the HEMO Study included a higher percentage of
African Americans than the overall hemodialysis popu-
lation, the study had a representative sample of partici-
pants with older age, diabetes, advanced comorbidity, and
employment status.
There are two approaches to evaluating the clinical im-
portance of the observed pain effect. One is to calculate
the effect size, the ratio of the observed mean change to
the standard deviation of the score in the population. In
this case, a change in the pain score of 4.5 points in a pop-
ulation having a baseline standard deviation in score of
27.9 represents an effect size of 0.16, smaller than with the
effect size of 0.2 proposed as a reasonable threshold for
a small effect [42]. On the other hand, one can also com-
pare the mean change associated with the treatment arms
to that observed with other interventions. For example,
treatment of post-herpetic neuralgia with placebo yielded
a 4.25 point improvement in pain, and with gabapentin,
a 10 point improvement [43]. The effect of high dose
hemodialysis on pain might be said to be like the differ-
ence between placebo and gabapentin for post-herpetic
neuralgia.
The reduction in pain from high dose hemodialysis had
not been hypothesized, and was relatively small. How-
ever, the effect on pain was seen consistently throughout
follow-up, and was strong enough that it seems unlikely
to represent chance alone. While the mechanism is not
yet clear, it is possible that small molecule clearance has
an impact on the perception of pain, whether directly or
indirectly. A previous study documents the impact of pain
on illness intrusiveness and quality of life in patients with
chronic kidney failure [44], and recent data suggest that
pain may be a much more important problem for this
population than previously recognized [45].
The statistically significant reduction in the decline
in the physical component summary score from high
dose hemodialysis represents an effect size of only 0.12,
well below the proposed threshold of 0.2. Its significance
should also be interpreted in the context of the circum-
stance that the pain scale contributes to the physical com-
ponent summary score and of the lack of effect of high
dose on physical component summary score observed in
year 1. In addition, one can compare it to clinical bench-
marks. Treatment of anemia in chronic kidney failure with
erythropoietin, raising the hematocrit by 4.6%, raises
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physical component summary score by a point [46]. A
year of chronic obstructive pulmonary disease is associ-
ated with a 3.3 point decline in physical component sum-
mary score, and a year of degenerative joint disease, with
a 2.1 point decline [28]. A year of usual care beginning
one month following kidney transplantation was associ-
ated with a change in physical component summary score
of 4.0 points [47]. These benchmarks provide context for
the HEMO Study finding that substituting high dose for
standard dose hemodialysis is associated with an average
difference of 1.27 points over 3 years. It is a very small
effect that is not consistent over 3 years of follow-up, and
it is not independent of the improvement in pain.
The effects of high dose and high flux on sleep were
small, and did not meet the standard of statistical signif-
icance established because of multiple hypothesis tests.
However, because of the prevalence of sleep disorders
among dialysis patients [48–52], the trend toward a ben-
efit deserves attention. Both for dose and for flux, the
intervention groups diverged only after the first year of
follow-up, and for both, the separation between the in-
tervention groups increased between the second and the
third year. This suggests the possibility that there may
have been a delayed effect, not seen at all during the first
year of follow-up.
There have been few longitudinal studies of qual-
ity of life in hemodialysis patients. The finding that
scores on physical domains of quality of life decreased
over time, whereas the mental and emotional aspects of
health-related quality of life remained stable, is consis-
tent with previous studies of incident patients remaining
on hemodialysis over 18 months [53]. However, the raw
scores are difficult to interpret because the HEMO Study
population had such a high attrition rate. Baseline health-
related quality of life scores of those patients who died
during follow-up were considerably lower than those of
other patients, and deteriorated more rapidly. This find-
ing is consistent with previous studies [11, 53]. The loss
of these patients from the sample would tend to increase
the average score of the surviving cohort because of the
attrition of sick patients.
Several limitations should be considered when inter-
preting the results of this study. First, as is always the
case with a multidimensional concept of health-related
quality of life, this study makes tests for significant dif-
ferences across several domains. To reduce the risk that
chance would lead to a falsely positive conclusion, the
domains thought most likely to show a significant differ-
ence were prespecified. Results were interpreted using
a Bonferroni adjustment. Second, the attrition was high.
The health-related quality of life scores at the end of the
3-year follow-up were contributed by only one third of
the original sample. Because the method of accounting
for deaths and dropouts can have a large influence on the
assessments of mean changes, several sensitivity analy-
ses were conducted to determine whether the results of
the dose and flux group comparisons were consistent un-
der different models for the missing data. The results for
the comparisons of the treatment groups were similar for
each model, indicating that our conclusions regarding the
effects of the dose and flux interventions are unlikely to
be artifacts of the method used to account for dropout.
CONCLUSION
Over 3 years’ follow-up in this large randomized, con-
trolled trial, higher dose hemodialysis was associated with
better physical health and with less bodily pain than was
standard dose, but these effects were small. High flux
hemodialysis was not associated with significant benefits
in any of the health-related quality of life domains ex-
amined. The health-related quality of life findings of the
HEMO Study are generalizable to three times a week
conventional hemodialysis and should not be applied to
other dialysis modalities or quotidian hemodialysis [54–
57]. Furthermore, the study intentionally confounded
hemodialysis treatment time with blood and dialysate
flow, and therefore the health-related quality of life re-
sults of dialysis dose should not be interpreted as implying
that treatment time reduction would have no impact on
health-related quality of life. The health-related quality
of life impact of the dialysis dose findings should be as-
sessed in light of no significant differences in morbidity
and mortality and the costs associated with higher dose
hemodialysis.
APPENDIX
Let yij denote the change in a scale score of patient i from baseline
to year j, j = 1, 2, . . . , 6, and let fi denote the duration of follow-up.
Let ui1 denote a 0 or 1 variable indicating if follow-up was terminated
due to death, and define ui2 = ui1 fi and ui3 = (1 − ui1)fi. Designate
the four cells of the 2 × 2 factorial design by k = 1, 2, 3, 4. Conditional
on the censoring variables ui1, ui2, and ui3, the basic model for the first
part of the mixture informative censoring analysis used in this paper is
yi j = b jk + j(ui1k1 + ui2k2 + ui3k3)
+ ui1max( j + 1 − fi , 0)k4
+ terms for centered baseline covariates + ei j , (A1)
where the b jk indicate the “baseline pattern” of mean changes within
cell k to each year j of follow-up, and the terms involving the uij represent
adjustments to the overall pattern of mean changes depending on the
values of the censoring variables. In particular, the term ui1max(j + 1 −
fi, 0)k4 allows for the possibility that the decline in the scale score may
accelerate in the final year prior to death. The residual terms eij are
assumed to be random variables with an unstructured covariance matrix
across time points to allow for all potential correlations. This model A1
was selected after evaluating a variety of alternative models for the
relationship between the censoring variables and the different scales
scores. For three of the 20 scales scores considered (role emotional,
mental health, and patient satisfaction), significant interactions (P <
0.05) were identified between the censoring variables and either the
dose or the flux intervention. For these three scales an extension of
model A1 was used in which the coefficients k1, k2, and k4 were allowed
to vary between the four cells of the design.
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The unconditional mean change of the scale score to year j in cell k
was estimated by:
hˆ jk = bˆ jk + j · (u¯1k kˆ1 + u¯2k kˆ2 + u¯3k kˆ3) + g¯ jk kˆ4
where the bˆ jk and kˆ1, kˆ2, kˆ3 and kˆ4 are restricted maximum likelihood
estimates of the corresponding parameters from the conditional model
(A1) obtained using PROC MIXED, and the u¯sk represent the mean of
the censoring variables within cell k. The definition of g¯ jk depends on the
model used to extrapolate beyond death. For model 1, which was used
for the main analyses presented in this report, g¯ jk = min{[u¯1k max( j +
1 − fi , 0)], 1}. For model 2, g¯ jk = u¯1k max( j + 1 − fi , 0), and for model
3, g¯ jk = 0.
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